FTC Sets “New Normal” For Study Data Reviews, Prioritizes Health Product Claims Enforcement
This article was originally published in The Tan Sheet
At the National Advertising Division Annual Conference, FTC Chairwoman Edith Ramirez said health claims and inadequate disclosures top the agency’s priorities following settlements with advertisers in 2013 and the recent Operation Full Disclosure initiative.
You may also be interested in...
FTC settles with operators of a bogus cognitive supplement sales ring for $26.2m; FDA warns on unapproved at-home head injury tests; and UK advertising regulator says HiSmile claims fail, P&G Always Discreet claims pass.
On the heels of FTC’s “Operation Full Disclosure,” which resulted in 60 warning letters, commission officials advise all advertisers to pay close attention to their disclosures and ensure they are clear and conspicuous. The initiative included review of 1,000 national television and print ads, and the agency says it will continue to monitor the advertising landscape for inadequate disclosure use.
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.